Application of guselkumab in refractory ulcerative colitis with endocytoscopy

Digestive and Liver Disease 2026 Open access

Read full text
Authors: Peng Bo, Zhongcheng Liu, Ting Xiao, Qin Guo
DOI: 10.1016/j.dld.2026.01.207
Cited by: 0

Abstract

A 26-year-old female with a 13-year history of ulcerative colitis (UC). In 2012, she developed recurrent abdominal pain with mucus-blood stool without apparent cause. Treatment with conventional aminosalicylates, corticosteroids, biologics (vedolizumab, infliximab, upadacitinib, and etc), and leukocyte adsorption yielded suboptimal results. While drug induction periods provided partial symptom relief, endoscopic performances revealed persistent inflammatory activity of varying degrees. Pre-medication endoscopic image of guselcizumab revealed marked distortion of microarchitecture, indicating significant histological inflammatory activity.

Fields of Study & Subjects

Inflammatory Bowel Disease Microscopic Colitis Ocular Diseases and Behçet’s Syndrome

Publication details

Journal / source
Digestive and Liver Disease
Volume
58
Issue
4
Pages
556–557
Publication date
10 February 2026
Language
EN